Cargando…
Clinical Characteristics and Treatment Outcomes of Scleromyxedema: A 10-Year Retrospective Survey
Scleromyxedema is a rare but important mucinosis disorder of the skin that is presented with dermatological manifestations such as waxy papules, diffuse induration, and nondermatologic involvements like neurological and renal disorders. We report a case series of the data regarding the characteristi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294944/ https://www.ncbi.nlm.nih.gov/pubmed/35950147 http://dx.doi.org/10.1159/000525211 |
_version_ | 1784749959342456832 |
---|---|
author | Ansari, Abtin Erfani, Zohre Daneshpazhooh, Maryam Mahmoudi, Leila Saffarian, Zahra Kamyab, Kambiz Mahmoudi, Hamidreza |
author_facet | Ansari, Abtin Erfani, Zohre Daneshpazhooh, Maryam Mahmoudi, Leila Saffarian, Zahra Kamyab, Kambiz Mahmoudi, Hamidreza |
author_sort | Ansari, Abtin |
collection | PubMed |
description | Scleromyxedema is a rare but important mucinosis disorder of the skin that is presented with dermatological manifestations such as waxy papules, diffuse induration, and nondermatologic involvements like neurological and renal disorders. We report a case series of the data regarding the characteristics and treatment of 14 patients diagnosed with scleromyxedema and their follow-up. Patients entered the study based on scleromyxedema diagnosis criteria. Comorbidities were also recorded to evaluate their effect on the treatment process. Clinicopathological and laboratory findings and responses to their treatment were evaluated separately. There was a significant improvement after administering intravenous immunoglobulin (IVIG). Despite the lack of a definite treatment for this condition, the present study shows that the application of IVIG can improve both cutaneous and systemic symptoms. Younger patients, in particular, responded significantly to the use of IVIG. More studies are required to investigate the potential efficacy of IVIG in the treatment of scleromyxedema. |
format | Online Article Text |
id | pubmed-9294944 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-92949442022-08-09 Clinical Characteristics and Treatment Outcomes of Scleromyxedema: A 10-Year Retrospective Survey Ansari, Abtin Erfani, Zohre Daneshpazhooh, Maryam Mahmoudi, Leila Saffarian, Zahra Kamyab, Kambiz Mahmoudi, Hamidreza Case Rep Dermatol Case Series Scleromyxedema is a rare but important mucinosis disorder of the skin that is presented with dermatological manifestations such as waxy papules, diffuse induration, and nondermatologic involvements like neurological and renal disorders. We report a case series of the data regarding the characteristics and treatment of 14 patients diagnosed with scleromyxedema and their follow-up. Patients entered the study based on scleromyxedema diagnosis criteria. Comorbidities were also recorded to evaluate their effect on the treatment process. Clinicopathological and laboratory findings and responses to their treatment were evaluated separately. There was a significant improvement after administering intravenous immunoglobulin (IVIG). Despite the lack of a definite treatment for this condition, the present study shows that the application of IVIG can improve both cutaneous and systemic symptoms. Younger patients, in particular, responded significantly to the use of IVIG. More studies are required to investigate the potential efficacy of IVIG in the treatment of scleromyxedema. S. Karger AG 2022-06-27 /pmc/articles/PMC9294944/ /pubmed/35950147 http://dx.doi.org/10.1159/000525211 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Series Ansari, Abtin Erfani, Zohre Daneshpazhooh, Maryam Mahmoudi, Leila Saffarian, Zahra Kamyab, Kambiz Mahmoudi, Hamidreza Clinical Characteristics and Treatment Outcomes of Scleromyxedema: A 10-Year Retrospective Survey |
title | Clinical Characteristics and Treatment Outcomes of Scleromyxedema: A 10-Year Retrospective Survey |
title_full | Clinical Characteristics and Treatment Outcomes of Scleromyxedema: A 10-Year Retrospective Survey |
title_fullStr | Clinical Characteristics and Treatment Outcomes of Scleromyxedema: A 10-Year Retrospective Survey |
title_full_unstemmed | Clinical Characteristics and Treatment Outcomes of Scleromyxedema: A 10-Year Retrospective Survey |
title_short | Clinical Characteristics and Treatment Outcomes of Scleromyxedema: A 10-Year Retrospective Survey |
title_sort | clinical characteristics and treatment outcomes of scleromyxedema: a 10-year retrospective survey |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294944/ https://www.ncbi.nlm.nih.gov/pubmed/35950147 http://dx.doi.org/10.1159/000525211 |
work_keys_str_mv | AT ansariabtin clinicalcharacteristicsandtreatmentoutcomesofscleromyxedemaa10yearretrospectivesurvey AT erfanizohre clinicalcharacteristicsandtreatmentoutcomesofscleromyxedemaa10yearretrospectivesurvey AT daneshpazhoohmaryam clinicalcharacteristicsandtreatmentoutcomesofscleromyxedemaa10yearretrospectivesurvey AT mahmoudileila clinicalcharacteristicsandtreatmentoutcomesofscleromyxedemaa10yearretrospectivesurvey AT saffarianzahra clinicalcharacteristicsandtreatmentoutcomesofscleromyxedemaa10yearretrospectivesurvey AT kamyabkambiz clinicalcharacteristicsandtreatmentoutcomesofscleromyxedemaa10yearretrospectivesurvey AT mahmoudihamidreza clinicalcharacteristicsandtreatmentoutcomesofscleromyxedemaa10yearretrospectivesurvey |